Drug
Efgartigimod Ph20 IN Stage B
Efgartigimod Ph20 IN Stage B: highest development phase Phase 2, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| efgartigimod PH20 SC in stage B NCT04281472 | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Latest
No recent events.
Follow Efgartigimod Ph20 IN Stage B on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.